I
Ingmar Lax
Researcher at Karolinska University Hospital
Publications - 101
Citations - 7479
Ingmar Lax is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Radiation therapy & Radiosurgery. The author has an hindex of 39, co-authored 96 publications receiving 7077 citations. Previous affiliations of Ingmar Lax include Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Stereotactic High Dose Fraction Radiation Therapy of Extracranial Tumors Using An Accelerator: Clinical experience of the first thirty-one patients
TL;DR: Some of the patients received stereotactic radiation therapy concomitantly to more than one target, in others new metastases were also treated which appeared during the follow-up period, and a local rate of no progressive disease of 80% was observed.
Journal ArticleDOI
Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
Pia Baumann,Jan Nyman,Morten Høyer,Berit Wennberg,Giovanna Gagliardi,Ingmar Lax,Ninni Drugge,Lars Ekberg,Signe Friesland,Karl-Axel Johansson,Jo-Åsmund Lund,Elisabeth Morhed,Kristina Nilsson,Nina Levin,Merete Paludan,Christer Sederholm,Anders Traberg,Lena Wittgren,Rolf Lewensohn +18 more
TL;DR: With a 3-year local tumor control rate higher than 90% with limited toxicity, SBRT emerges as state-of-the-art treatment for medically inoperable stage I NSCLC and may even challenge surgery in operable instances.
Journal ArticleDOI
Stereotactic Radiotherapy of Malignancies in the Abdomen: Methodological aspects
TL;DR: The reproducibility in the stereotactic system of tumours in the liver and the lung was found to be within 5-8 mm for 90% of the patient set-ups, and the diaphragmatic movements were reduced by applying a pressure on the abdomen.
Journal ArticleDOI
Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer.
TL;DR: In this paper, the authors presented an analysis of long-term survival among 960 patients with primary breast cancer included in a randomized trial of pre- or postoperative radiation therapy (45 Gy/5 weeks) versus surgery alone.
Journal ArticleDOI
The role of radiotherapy in treatment of stage I non-small cell lung cancer
TL;DR: Dose escalation, in a setting with conformal RT using involved field or stereotactic RT, should be the focus of developmental therapeutic strategies with inoperable stage I NSCLC to improve local control and survival.